DK1660135T3 - Fremgangsm de til at behandle hepatocellul re carcinomer - Google Patents

Fremgangsm de til at behandle hepatocellul re carcinomer

Info

Publication number
DK1660135T3
DK1660135T3 DK04777732T DK04777732T DK1660135T3 DK 1660135 T3 DK1660135 T3 DK 1660135T3 DK 04777732 T DK04777732 T DK 04777732T DK 04777732 T DK04777732 T DK 04777732T DK 1660135 T3 DK1660135 T3 DK 1660135T3
Authority
DK
Denmark
Prior art keywords
zvegf3
treating hepatocellular
procedures
mammal
hepatocellular carcinomas
Prior art date
Application number
DK04777732T
Other languages
Danish (da)
English (en)
Inventor
Thomas E Palmer
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1660135T3 publication Critical patent/DK1660135T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04777732T 2003-07-25 2004-07-09 Fremgangsm de til at behandle hepatocellul re carcinomer DK1660135T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49004703P 2003-07-25 2003-07-25
PCT/US2004/021835 WO2005011742A1 (en) 2003-07-25 2004-07-09 Method of treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
DK1660135T3 true DK1660135T3 (da) 2009-09-07

Family

ID=34115347

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04777732T DK1660135T3 (da) 2003-07-25 2004-07-09 Fremgangsm de til at behandle hepatocellul re carcinomer

Country Status (9)

Country Link
US (4) US20050191304A1 (de)
EP (1) EP1660135B1 (de)
JP (1) JP4709145B2 (de)
AT (1) ATE432716T1 (de)
CA (1) CA2529798C (de)
DE (1) DE602004021395D1 (de)
DK (1) DK1660135T3 (de)
ES (1) ES2326978T3 (de)
WO (1) WO2005011742A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
MX2014012843A (es) 2012-04-24 2017-01-23 Thrombogenics Nv Anticuerpos anti-pdgf-c.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2354325C (en) * 1998-12-07 2011-08-16 Zymogenetics, Inc. Growth factor homolog zvegf3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis

Also Published As

Publication number Publication date
DE602004021395D1 (de) 2009-07-16
EP1660135B1 (de) 2009-06-03
US20050191304A1 (en) 2005-09-01
US20070054858A1 (en) 2007-03-08
US20090028865A1 (en) 2009-01-29
JP4709145B2 (ja) 2011-06-22
CA2529798A1 (en) 2005-02-10
JP2006528663A (ja) 2006-12-21
EP1660135A1 (de) 2006-05-31
ES2326978T3 (es) 2009-10-22
CA2529798C (en) 2014-09-16
US20110052588A1 (en) 2011-03-03
WO2005011742A1 (en) 2005-02-10
ATE432716T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
WO2008154638A8 (en) Antagonists of the receptor for advanced glycation end-products (rage)
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
BR0317898A (pt) Imunoterapia de malignidades de células b e doenças auto-imunes usando anticorpos não conjugados e conjugados, combinações de anticorpos e proteìnas de fusão
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
MA32806B1 (fr) Thérapie de combinaison avec des peptides époxycétones
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
ATE389404T1 (de) Kappa-opioid-rezeptor-liganden
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
WO2003048120A3 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
WO2008013954A3 (en) Tyrosine phosphorylation sites
WO2008054597A3 (en) Tyrosine phosphorylation sites
EP1195166A3 (de) Verwendung von einem Vasopressin-Antagonist wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
ATE404555T1 (de) Neue mch-rezeptorantagonisten
WO2008013934A8 (en) Tyrosine phosphorylation sites
WO2006071775A3 (en) Novel compounds useful for bradykinin b1 receptor antagonism
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
ATE485296T1 (de) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit
ATE432716T1 (de) Verfahren zur behandlung von hepatozellulärem karzinom
WO2007044321A3 (en) Latent procytotoxins and uses thereof
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau